CG&D
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cell Growth & Differentiation

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Butler, R.
Right arrow Articles by Young, C. Y. F.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Butler, R.
Right arrow Articles by Young, C. Y. F.
Cell Growth & Differentiation Vol. 11, 49-61, January 2000
© 2000 American Association for Cancer Research


Articles

Nonapoptotic Cell Death Associated with S-Phase Arrest of Prostate Cancer Cells via the Peroxisome Proliferator-activated Receptor {gamma} Ligand, 15-Deoxy-{Delta}12,14- prostaglandin J21

Rachel Butler2, Susan H. Mitchell, Donald J. Tindall and Charles Y. F. Young3

Departments of Urology [R. B., S. H. M., D. J. T., C. Y. F. Y.] and Biochemistry [D. J. T., C. Y. F. Y.] and Molecular Biology, Mayo Clinic/Foundation, Rochester, Minnesota 55905

Abstract

15-Deoxy-{Delta}12,14-prostaglandin J2 (15d-PGJ2) is a highly specific activator of the peroxisome proliferator-activated receptor {gamma} (PPAR-{gamma}). We investigated the effect of 15d-PGJ2 on three human prostate cancer cell lines, LNCaP, DU145, and PC-3. Western blotting demonstrated that PPAR-{gamma}1 is expressed predominantly in untreated prostate cancer cells. Treatment with 15d-PGJ2 caused an increase in the expression of PPAR-{gamma}2, whereas PPAR-{gamma}1 remained at basal levels. PPARs {alpha} and ß were not detected in these cells. Lack of lipid accumulation, increase in CCAAT/enhancer binding proteins (C/EBPs), or expression of aP2 mRNA indicated that adipocytic differentiation is not induced in these cells by 15d-PGJ2. 15d-PGJ2 and other PPAR-{gamma} activators induced cell death in all three cell lines at concentrations as low as 2.5 µM (similar to the Kd of PPAR-{gamma} for this ligand), coinciding with an accumulation of cells in the S-phase of the cell cycle. Activators for PPAR-{alpha} and ß did not induce cell death. Staining with trypan blue and propidium iodide suggested that, although the plasma membrane appears intact by electron microscopy, disturbances are evident as early as 2 h after treatment. Mitochondrial transmembrane potentials are significantly reduced by 15d-PGJ2 treatment. In addition, treatment with 15d-PGJ2 resulted in cytoplasmic changes, which are indicative of type 2 (autophagic), nonapoptotic programmed cell death.




This article has been cited by other articles:


Home page
Anticancer ResHome page
N. PITULIS, E. PAPAGEORGIOU, R. TENTA, P. LEMBESSIS, and M. KOUTSILIERIS
IL-6 and PPAR{gamma} Signalling in Human PC-3 Prostate Cancer Cells
Anticancer Res, June 1, 2009; 29(6): 2331 - 2337.
[Abstract] [Full Text] [PDF]


Home page
Cancer Epidemiol. Biomarkers Prev.Home page
K. Singletary and J. Milner
Diet, Autophagy, and Cancer: A Review
Cancer Epidemiol. Biomarkers Prev., July 1, 2008; 17(7): 1596 - 1610.
[Abstract] [Full Text] [PDF]


Home page
Mol. Pharmacol.Home page
K. Y. Kim, J. H. Ahn, and H. G. Cheon
Apoptotic Action of Peroxisome Proliferator-Activated Receptor-{gamma} Activation in Human Non Small-Cell Lung Cancer Is Mediated via Proline Oxidase-Induced Reactive Oxygen Species Formation
Mol. Pharmacol., September 1, 2007; 72(3): 674 - 685.
[Abstract] [Full Text] [PDF]


Home page
Mol. Cell. Biol.Home page
J.-S. Annicotte, I. Iankova, S. Miard, V. Fritz, D. Sarruf, A. Abella, M.-L. Berthe, D. Noel, A. Pillon, F. Iborra, et al.
Peroxisome Proliferator-Activated Receptor {gamma} Regulates E-Cadherin Expression and Inhibits Growth and Invasion of Prostate Cancer
Mol. Cell. Biol., October 15, 2006; 26(20): 7561 - 7574.
[Abstract] [Full Text] [PDF]


Home page
Molecular Cancer TherapeuticsHome page
S. Nakata, T. Yoshida, T. Shiraishi, M. Horinaka, J. Kouhara, M. Wakada, and T. Sakai
15-Deoxy-{Delta}12,14-prostaglandin J2 induces death receptor 5 expression through mRNA stabilization independently of PPAR{gamma} and potentiates TRAIL-induced apoptosis.
Mol. Cancer Ther., July 1, 2006; 5(7): 1827 - 1835.
[Abstract] [Full Text] [PDF]


Home page
Endocr Relat CancerHome page
K-M Fung, E N S Samara, C Wong, A Metwalli, R Krlin, B Bane, C Z Liu, J T Yang, J V Pitha, D J Culkin, et al.
Increased expression of type 2 3{alpha}-hydroxysteroid dehydrogenase/type 5 17{beta}-hydroxysteroid dehydrogenase (AKR1C3) and its relationship with androgen receptor in prostate carcinoma.
Endocr. Relat. Cancer, March 1, 2006; 13(1): 169 - 180.
[Abstract] [Full Text] [PDF]


Home page
GutHome page
H A Patsos, D J Hicks, R R H Dobson, A Greenhough, N Woodman, J D Lane, A C Williams, and C Paraskeva
The endogenous cannabinoid, anandamide, induces cell death in colorectal carcinoma cells: a possible role for cyclooxygenase 2
Gut, December 1, 2005; 54(12): 1741 - 1750.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
J. Kim, P. Yang, M. Suraokar, A. L. Sabichi, N. D. Llansa, G. Mendoza, V. Subbarayan, C. J. Logothetis, R. A. Newman, S. M. Lippman, et al.
Suppression of Prostate Tumor Cell Growth by Stromal Cell Prostaglandin D Synthase-Derived Products
Cancer Res., July 15, 2005; 65(14): 6189 - 6198.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
R. Piva, P. Gianferretti, A. Ciucci, R. Taulli, G. Belardo, and M. G. Santoro
15-Deoxy-{Delta}12,14-prostaglandin J2 induces apoptosis in human malignant B cells: an effect associated with inhibition of NF-{kappa}B activity and down-regulation of antiapoptotic proteins
Blood, February 15, 2005; 105(4): 1750 - 1758.
[Abstract] [Full Text] [PDF]


Home page
Cancer Epidemiol. Biomarkers Prev.Home page
A. L. Sabichi, V. Subbarayan, N. Llansa, S. M. Lippman, and D. G. Menter
Peroxisome Proliferator-Activated Receptor-{gamma} Suppresses Cyclooxygenase-2 Expression in Human Prostate Cells
Cancer Epidemiol. Biomarkers Prev., November 1, 2004; 13(11): 1704 - 1709.
[Abstract] [Full Text] [PDF]


Home page
Cancer Epidemiol. Biomarkers Prev.Home page
V. Subbarayan, A. L. Sabichi, J. Kim, N. Llansa, C. J. Logothetis, S. M. Lippman, and D. G. Menter
Differential Peroxisome Proliferator-Activated Receptor-{gamma} Isoform Expression and Agonist Effects in Normal and Malignant Prostate Cells
Cancer Epidemiol. Biomarkers Prev., November 1, 2004; 13(11): 1710 - 1716.
[Abstract] [Full Text] [PDF]


Home page
Biochem. J.Home page
H. A. RODWAY, A. N. HUNT, J. A. KOHLER, A. D. POSTLE, and K. A. LILLYCROP
Lysophosphatidic acid attenuates the cytotoxic effects and degree of peroxisome proliferator-activated receptor {gamma} activation induced by 15-deoxy{Delta}12,14-prostaglandin J2 in neuroblastoma cells
Biochem. J., August 15, 2004; 382(1): 83 - 91.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
J. C. Desmond, J. C. Mountford, M. T. Drayson, E. A. Walker, M. Hewison, J. P. Ride, Q. T. Luong, R. E. Hayden, E. F. Vanin, and C. M. Bunce
The Aldo-Keto Reductase AKR1C3 Is a Novel Suppressor of Cell Differentiation That Provides a Plausible Target for the Non-Cyclooxygenase-dependent Antineoplastic Actions of Nonsteroidal Anti-Inflammatory Drugs
Cancer Res., January 15, 2003; 63(2): 505 - 512.
[Abstract] [Full Text] [PDF]


Home page
J Biol ChemHome page
L. C. Hsi, L. C. Wilson, and T. E. Eling
Opposing Effects of 15-Lipoxygenase-1 and -2 Metabolites on MAPK Signaling in Prostate: ALTERATION IN PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR {gamma}
J. Biol. Chem., October 25, 2002; 277(43): 40549 - 40556.
[Abstract] [Full Text] [PDF]


Home page
Molecular Cancer TherapeuticsHome page
L. Kopelovich, J. R. Fay, R. I. Glazer, and J. A. Crowell
Peroxisome Proliferator-activated Receptor Modulators As Potential Chemopreventive Agents
Mol. Cancer Ther., March 1, 2002; 1(5): 357 - 363.
[Abstract] [Full Text] [PDF]


Home page
Biol. Reprod.Home page
P. D. Schoppee, J. C. Garmey, and J. D. Veldhuis
Putative Activation of the Peroxisome Proliferator-Activated Receptor {gamma} Impairs Androgen and Enhances Progesterone Biosynthesis in Primary Cultures of Porcine Theca Cells
Biol Reprod, January 1, 2002; 66(1): 190 - 198.
[Abstract] [Full Text]


Home page
J Biol ChemHome page
J. G. Hunter, M. F. van Delft, R. A. Rachubinski, and J. P. Capone
Peroxisome Proliferator-activated Receptor {gamma} Ligands Differentially Modulate Muscle Cell Differentiation and MyoD Gene Expression via Peroxisome Proliferator-activated Receptor {gamma}-dependent and -independent Pathways
J. Biol. Chem., October 12, 2001; 276(41): 38297 - 38306.
[Abstract] [Full Text] [PDF]


Home page
J Investig MedHome page
C. E. Clay, A. M. Namen, G.-i. Atsumi, A. J. Trimboli, A. N. Fonteh, K. P. High, and F. H. Chilton
Magnitude of Peroxisome Proliferator-Activated Receptor-{gamma} Activation is Associated With Important and Seemingly Opposite Biological Responses in Breast Cancer Cells
J Investig Med, September 1, 2001; 49(5): 413 - 420.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Endocrinol. Metab.Home page
C. J. Hupfeld and R. H. Weiss
TZDs inhibit vascular smooth muscle cell growth independently of the cyclin kinase inhibitors p21 and p27
Am J Physiol Endocrinol Metab, August 1, 2001; 281(2): E207 - E216.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
S. Han, R. K. Wada, and N. Sidell
Differentiation of Human Neuroblastoma by Phenylacetate Is Mediated by Peroxisome Proliferator-activated Receptor {{gamma}}
Cancer Res., May 1, 2001; 61(10): 3998 - 4002.
[Abstract] [Full Text]


Home page
Cancer Res.Home page
S. B. Shappell, R. A. Gupta, S. Manning, R. Whitehead, W. E. Boeglin, C. Schneider, T. Case, J. Price, G. S. Jack, T. M. Wheeler, et al.
15S-Hydroxyeicosatetraenoic Acid Activates Peroxisome Proliferator-activated Receptor {{gamma}} and Inhibits Proliferation in PC3 Prostate Carcinoma Cells
Cancer Res., January 1, 2001; 61(2): 497 - 503.
[Abstract] [Full Text]


Home page
Cancer Res.Home page
D. K. Vanaja, M. E. Grossmann, E. Celis, and C. Y. F. Young
Tumor Prevention and Antitumor Immunity with Heat Shock Protein 70 Induced by 15-Deoxy-{{Delta}}12,14-prostaglandin J2 in Transgenic Adenocarcinoma of Mouse Prostate Cells
Cancer Res., September 1, 2000; 60(17): 4714 - 4718.
[Abstract] [Full Text]


Home page
J Biol ChemHome page
J. G. Hunter, M. F. van Delft, R. A. Rachubinski, and J. P. Capone
Peroxisome proliferator-activated receptor gamma ligands differentially modulate muscle cell differentiation and MyoD gene expression via peroxisome proliferator-activated receptor gamma-dependent and -independent pathways
J. Biol. Chem., July 25, 2001; (2001) 103594200.
[Abstract] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cell Growth & Differentiation
Copyright © 2000 by the American Association of Cancer Research.